BABIO Launches High-Accuracy HCV Antibody Rapid Test for Global Markets

Jinan BABIO Biotechnology Co., Ltd. (BABIO), a leading Chinese manufacturer of rapid diagnostic solutions, proudly introduces its HCV (Hepatitis C Virus) Antibody Rapid Test — a highly reliable solution for early screening and auxiliary diagnosis of hepatitis C infections.

Designed using advanced colloidal gold immunochromatography, the test delivers rapid, qualitative results within 15 minutes, making it ideal for clinical screening, healthcare facilities, and public health programs worldwide.

With growing global focus on hepatitis elimination initiatives led by the World Health Organization (WHO), the need for accurate, easy-to-use, and cost-effective diagnostic tools has never been greater. BABIO’s HCV Rapid Test meets international standards of sensitivity, specificity, and stability, ensuring dependable detection in both serum and plasma samples.

Key Advantages:

• ✅ Fast Results: Detects HCV antibodies in 15 minutes.

• ✅ High Sensitivity & Specificity: Uses recombinant antigen for precise detection.

• ✅ User-Friendly: No special equipment required.

• ✅ Ideal for Global Use: Suitable for professional screening in hospitals, clinics, and laboratories.

As part of BABIO’s commitment to global public health and infectious disease control, this new HCV test supports healthcare providers in Europe, Africa, Latin America, and Southeast Asia with trustworthy diagnostic performance and competitive pricing.

For detailed product specifications or cooperation opportunities, please visit the official BABIO website: https://www.babiomed.com.

#HCVRapidTest #HepatitisC #InfectiousDiseaseTesting #BABIO #DiagnosticSolutions #PointOfCareTesting #HealthcareInnovation #GlobalHealth